{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T04:13:51Z","timestamp":1768882431950,"version":"3.49.0"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T00:00:00Z","timestamp":1731628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T00:00:00Z","timestamp":1731628800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Host-directed therapies aiming to strengthen the body\u2019s immune system, represent an underexplored opportunity to improve treatment of tuberculosis (TB). We have previously shown in <jats:italic>Mycobacterium tuberculosis<\/jats:italic> (Mtb)-infection models and clinical trials that treatment with the histone deacetylase (HDAC) inhibitor, phenylbutyrate (PBA), can restore Mtb-induced impairment of antimicrobial responses and improve clinical outcomes in pulmonary TB. In this study, we evaluated the efficacy of different groups of HDAC inhibitors to reduce Mtb growth in human immune cells. A panel of 21 selected HDAC inhibitors with different specificities that are known to modulate infection or inflammation was tested using high-content live-cell imaging and analysis. Monocyte-derived macrophages or bulk peripheral blood cells (PBMCs) were infected with the green fluorescent protein (GFP)-expressing Mtb strains H37Ra or H37Rv and treated with HDAC inhibitors in the micromolar range in parallel with a combination of the first-line antibiotics, rifampicin, and isoniazid. Host cell viability in HDAC inhibitor treated cell cultures was monitored with Cytotox-red. Seven HDAC inhibitors were identified that reduced Mtb growth in macrophages\u2009&gt;\u200945\u201375% compared to average 40% for PBA. The most effective compounds were inhibitors of the class III HDAC proteins, the sirtuins. While these compounds may exhibit their effects by improving macrophage function, one of the sirtuin inhibitors, tenovin, was also highly effective in extracellular killing of Mtb bacilli. Antimicrobial synergy testing using checkerboard assays revealed additive effects between selected sirtuin inhibitors and subinhibitory concentrations of rifampicin or isoniazid. A customized macrophage RNA array including 23 genes associated with cytokines, chemokines and inflammation, suggested that Mtb-infected macrophages are differentially modulated by the sirtuin inhibitors as compared to PBA. Altogether, these results demonstrated that sirtuin inhibitors may be further explored as promising host-directed compounds to support immune functions and reduce intracellular growth of Mtb in human cells.<\/jats:p>","DOI":"10.1038\/s41598-024-79136-1","type":"journal-article","created":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T09:15:06Z","timestamp":1731662106000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Sirtuin inhibitors reduce intracellular growth of M. tuberculosis in human macrophages via modulation of host cell immunity"],"prefix":"10.1038","volume":"14","author":[{"given":"Sadaf","family":"Kalsum","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mira","family":"Akber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco Giulio","family":"Loreti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Blanka","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Danielson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Lerm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanna","family":"Brighenti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,15]]},"reference":[{"key":"79136_CR1","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/s41579-022-00731-y","volume":"20","author":"VA Dartois","year":"2022","unstructured":"Dartois, V. A. & Rubin, E. J. Anti-tuberculosis treatment strategies and drug development: challenges and priorities. Nat. Rev. Microbiol. 20, 685\u2013701. https:\/\/doi.org\/10.1038\/s41579-022-00731-y (2022).","journal-title":"Nat. Rev. Microbiol."},{"key":"79136_CR2","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/S1473-3099(23)00498-X","volume":"24","author":"I Barilar","year":"2024","unstructured":"Barilar, I. et al. Emergence of bedaquiline-resistant tuberculosis and of multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis strains with rpoB Ile491Phe mutation not detected by Xpert MTB\/RIF in Mozambique: a retrospective observational study. Lancet Infect. Dis. 24, 297\u2013307. https:\/\/doi.org\/10.1016\/S1473-3099(23)00498-X (2024).","journal-title":"Lancet Infect. Dis."},{"key":"79136_CR3","doi-asserted-by":"publisher","first-page":"S62","DOI":"10.1016\/j.ijid.2019.01.039","volume":"80S","author":"M Rao","year":"2019","unstructured":"Rao, M. et al. Improving treatment outcomes for MDR-TB - Novel host-directed therapies and personalised medicine of the future. Int. J. Infect. Dis. 80S, S62\u2013S67. https:\/\/doi.org\/10.1016\/j.ijid.2019.01.039 (2019).","journal-title":"Int. J. Infect. Dis."},{"key":"79136_CR4","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/s41385-019-0226-5","volume":"13","author":"C Young","year":"2020","unstructured":"Young, C. & Walzl, G. Du Plessis, N. Therapeutic host-directed strategies to improve outcome in tuberculosis. Mucosal Immunol. 13, 190\u2013204. https:\/\/doi.org\/10.1038\/s41385-019-0226-5 (2020).","journal-title":"Mucosal Immunol."},{"key":"79136_CR5","doi-asserted-by":"publisher","first-page":"e353","DOI":"10.1002\/mco2.353","volume":"4","author":"J Yang","year":"2023","unstructured":"Yang, J., Zhang, L., Qiao, W. & Luo, Y. Mycobacterium tuberculosis: Pathogenesis and therapeutic targets. MedComm (2020). 4, e353. https:\/\/doi.org\/10.1002\/mco2.353 (2023).","journal-title":"MedComm (2020)"},{"key":"79136_CR6","doi-asserted-by":"publisher","first-page":"635335","DOI":"10.3389\/fcimb.2021.635335","volume":"11","author":"JH Park","year":"2021","unstructured":"Park, J. H., Shim, D., Kim, K. E. S., Lee, W. & Shin, S. J. Understanding metabolic regulation between host and pathogens: New opportunities for the development of improved therapeutic strategies against Mycobacterium tuberculosis infection. Front. Cell. Infect. Microbiol. 11, 635335. https:\/\/doi.org\/10.3389\/fcimb.2021.635335 (2021).","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"79136_CR7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1164\/rccm.201311-2106PP","volume":"190","author":"CW Ong","year":"2014","unstructured":"Ong, C. W., Elkington, P. T. & Friedland, J. S. Tuberculosis, pulmonary cavitation, and matrix metalloproteinases. Am. J. Respir Crit. Care Med. 190, 9\u201318. https:\/\/doi.org\/10.1164\/rccm.201311-2106PP (2014).","journal-title":"Am. J. Respir Crit. Care Med."},{"key":"79136_CR8","doi-asserted-by":"publisher","first-page":"101672","DOI":"10.1016\/j.smim.2022.101672","volume":"65","author":"D Tiwari","year":"2023","unstructured":"Tiwari, D. & Martineau, A. R. Inflammation-mediated tissue damage in pulmonary tuberculosis and host-directed therapeutic strategies. Semin Immunol. 65, 101672. https:\/\/doi.org\/10.1016\/j.smim.2022.101672 (2023).","journal-title":"Semin Immunol."},{"key":"79136_CR9","doi-asserted-by":"publisher","first-page":"537","DOI":"10.2217\/epi.16.1","volume":"8","author":"M Kathirvel","year":"2016","unstructured":"Kathirvel, M. & Mahadevan, S. The role of epigenetics in tuberculosis infection. Epigenomics. 8, 537\u2013549. https:\/\/doi.org\/10.2217\/epi.16.1 (2016).","journal-title":"Epigenomics"},{"key":"79136_CR10","doi-asserted-by":"publisher","first-page":"455","DOI":"10.2217\/epi-2019-0187","volume":"12","author":"S Tarashi","year":"2020","unstructured":"Tarashi, S. et al. The inter-talk between Mycobacterium tuberculosis and the epigenetic mechanisms. Epigenomics. 12, 455\u2013469. https:\/\/doi.org\/10.2217\/epi-2019-0187 (2020).","journal-title":"Epigenomics"},{"key":"79136_CR11","doi-asserted-by":"publisher","first-page":"5687","DOI":"10.4049\/jimmunol.174.9.5687","volume":"174","author":"Y Wang","year":"2005","unstructured":"Wang, Y., Curry, H. M., Zwilling, B. S. & Lafuse, W. P. Mycobacteria inhibition of IFN-gamma induced HLA-DR gene expression by up-regulating histone deacetylation at the promoter region in human THP-1 monocytic cells. J. Immunol. 174, 5687\u20135694. https:\/\/doi.org\/10.4049\/jimmunol.174.9.5687 (2005).","journal-title":"J. Immunol."},{"key":"79136_CR12","doi-asserted-by":"publisher","first-page":"90","DOI":"10.3389\/fcimb.2015.00090","volume":"5","author":"A Chandran","year":"2015","unstructured":"Chandran, A. et al. Mycobacterium tuberculosis infection induces HDAC1-Mediated suppression of IL-12B gene expression in macrophages. Front. Cell. Infect. Microbiol. 5, 90. https:\/\/doi.org\/10.3389\/fcimb.2015.00090 (2015).","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"79136_CR13","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/j.bbrc.2016.04.045","volume":"473","author":"L Duan","year":"2016","unstructured":"Duan, L., Yi, M., Chen, J., Li, S. & Chen, W. Mycobacterium tuberculosis EIS gene inhibits macrophage autophagy through up-regulation of IL-10 by increasing the acetylation of histone H3. Biochem. Biophys. Res. Commun. 473, 1229\u20131234. https:\/\/doi.org\/10.1016\/j.bbrc.2016.04.045 (2016).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"79136_CR14","doi-asserted-by":"publisher","first-page":"e62","DOI":"10.1038\/cti.2015.46","volume":"5","author":"K Das Gupta","year":"2016","unstructured":"Das Gupta, K., Shakespear, M. R., Iyer, A., Fairlie, D. P. & Sweet, M. J. Histone deacetylases in monocyte\/macrophage development, activation and metabolism: refining HDAC targets for inflammatory and infectious diseases. Clin. Transl Immunol. 5, e62. https:\/\/doi.org\/10.1038\/cti.2015.46 (2016).","journal-title":"Clin. Transl Immunol."},{"key":"79136_CR15","doi-asserted-by":"publisher","first-page":"104193","DOI":"10.1016\/j.drudis.2024.104193","volume":"29","author":"MF Bhat","year":"2024","unstructured":"Bhat, M. F. et al. Impact of HDAC inhibitors on macrophage polarization to enhance innate immunity against infections. Drug Discov Today. 29, 104193. https:\/\/doi.org\/10.1016\/j.drudis.2024.104193 (2024).","journal-title":"Drug Discov Today"},{"key":"79136_CR16","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1016\/j.jaci.2013.08.039","volume":"132","author":"M Lopez-Bravo","year":"2013","unstructured":"Lopez-Bravo, M. et al. IL-4 blocks TH1-polarizing\/inflammatory cytokine gene expression during monocyte-derived dendritic cell differentiation through histone hypoacetylation. J. Allergy Clin. Immunol. 132, 1409\u20131419. https:\/\/doi.org\/10.1016\/j.jaci.2013.08.039 (2013).","journal-title":"J. Allergy Clin. Immunol."},{"key":"79136_CR17","doi-asserted-by":"publisher","first-page":"841716","DOI":"10.3389\/fimmu.2022.841716","volume":"13","author":"C Ripamonti","year":"2022","unstructured":"Ripamonti, C. et al. HDAC inhibition as potential therapeutic strategy to restore the deregulated Immune response in severe COVID-19. Front. Immunol. 13, 841716. https:\/\/doi.org\/10.3389\/fimmu.2022.841716 (2022).","journal-title":"Front. Immunol."},{"key":"79136_CR18","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1080\/15548627.2015.1075110","volume":"11","author":"RS Rekha","year":"2015","unstructured":"Rekha, R. S. et al. Phenylbutyrate induces LL-37-dependent autophagy and intracellular killing of Mycobacterium tuberculosis in human macrophages. Autophagy. 11, 1688\u20131699. https:\/\/doi.org\/10.1080\/15548627.2015.1075110 (2015).","journal-title":"Autophagy"},{"key":"79136_CR19","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1093\/infdis\/jiab100","volume":"224","author":"J Rao Muvva","year":"2021","unstructured":"Rao Muvva, J. et al. Immunomodulatory agents Combat Multidrug-resistant tuberculosis by improving Antimicrobial immunity. J. Infect. Dis. 224, 332\u2013344. https:\/\/doi.org\/10.1093\/infdis\/jiab100 (2021).","journal-title":"J. Infect. Dis."},{"key":"79136_CR20","doi-asserted-by":"publisher","first-page":"e0138340","DOI":"10.1371\/journal.pone.0138340","volume":"10","author":"A Mily","year":"2015","unstructured":"Mily, A. et al. Significant effects of oral phenylbutyrate and vitamin D3 adjunctive therapy in pulmonary tuberculosis: a Randomized Controlled Trial. PLoS One. 10, e0138340. https:\/\/doi.org\/10.1371\/journal.pone.0138340 (2015).","journal-title":"PLoS One"},{"key":"79136_CR21","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1111\/joim.12767","volume":"284","author":"A Bekele","year":"2018","unstructured":"Bekele, A. et al. Daily adjunctive therapy with vitamin D(3) and phenylbutyrate supports clinical recovery from pulmonary tuberculosis: a randomized controlled trial in Ethiopia. J. Intern. Med. 284, 292\u2013306. https:\/\/doi.org\/10.1111\/joim.12767 (2018).","journal-title":"J. Intern. Med."},{"key":"79136_CR22","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1186\/s12879-018-3203-9","volume":"18","author":"RS Rekha","year":"2018","unstructured":"Rekha, R. S. et al. Immune responses in the treatment of drug-sensitive pulmonary tuberculosis with phenylbutyrate and vitamin D(3) as host directed therapy. BMC Infect. Dis. 18, 303. https:\/\/doi.org\/10.1186\/s12879-018-3203-9 (2018).","journal-title":"BMC Infect. Dis."},{"key":"79136_CR23","first-page":"166","volume":"3","author":"HJ Kim","year":"2011","unstructured":"Kim, H. J. & Bae, S. C. Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs. Am. J. Transl Res. 3, 166\u2013179 (2011).","journal-title":"Am. J. Transl Res."},{"key":"79136_CR24","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/s41576-018-0074-2","volume":"20","author":"M Berdasco","year":"2019","unstructured":"Berdasco, M. & Esteller, M. Clinical epigenetics: seizing opportunities for translation. Nat. Rev. Genet. 20, 109\u2013127. https:\/\/doi.org\/10.1038\/s41576-018-0074-2 (2019).","journal-title":"Nat. Rev. Genet."},{"key":"79136_CR25","doi-asserted-by":"publisher","first-page":"945","DOI":"10.4155\/fmc.14.44","volume":"6","author":"J Hu","year":"2014","unstructured":"Hu, J., Jing, H. & Lin, H. Sirtuin inhibitors as anticancer agents. Future Med. Chem. 6, 945\u2013966. https:\/\/doi.org\/10.4155\/fmc.14.44 (2014).","journal-title":"Future Med. Chem."},{"key":"79136_CR26","doi-asserted-by":"publisher","first-page":"3157","DOI":"10.3389\/fimmu.2019.03157","volume":"10","author":"J Rao Muvva","year":"2019","unstructured":"Rao Muvva, J., Parasa, V. R., Lerm, M., Svensson, M. & Brighenti, S. Polarization of human monocyte-derived cells with vitamin D promotes control of Mycobacterium tuberculosis infection. Front. Immunol. 10, 3157. https:\/\/doi.org\/10.3389\/fimmu.2019.03157 (2019).","journal-title":"Front. Immunol."},{"key":"79136_CR27","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1177\/2472555220942764","volume":"25","author":"H Bar","year":"2020","unstructured":"Bar, H. & Zweifach, A. Z\u2019 does not need to be >\u20090.5. SLAS Discov. 25, 1000\u20131008. https:\/\/doi.org\/10.1177\/2472555220942764 (2020).","journal-title":"SLAS Discov"},{"key":"79136_CR28","doi-asserted-by":"publisher","first-page":"4577","DOI":"10.1111\/bcp.14889","volume":"87","author":"AD Bondarev","year":"2021","unstructured":"Bondarev, A. D. et al. Recent developments of HDAC inhibitors: emerging indications and novel molecules. Br. J. Clin. Pharmacol. 87, 4577\u20134597. https:\/\/doi.org\/10.1111\/bcp.14889 (2021).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"79136_CR29","doi-asserted-by":"publisher","first-page":"3885","DOI":"10.1007\/s00018-014-1656-6","volume":"71","author":"J Zhang","year":"2014","unstructured":"Zhang, J. & Zhong, Q. Histone deacetylase inhibitors and cell death. Cell. Mol. Life Sci. 71, 3885\u20133901. https:\/\/doi.org\/10.1007\/s00018-014-1656-6 (2014).","journal-title":"Cell. Mol. Life Sci."},{"key":"79136_CR30","doi-asserted-by":"publisher","first-page":"e230143","DOI":"10.1590\/0074-02760230143","volume":"118","author":"A Rodriguez-Carlos","year":"2023","unstructured":"Rodriguez-Carlos, A. et al. Histone deacetylase (HDAC) inhibitors- based drugs are effective to control Mycobacterium tuberculosis infection and promote the sensibility for rifampicin in MDR strain. Mem. Inst. Oswaldo Cruz. 118, e230143. https:\/\/doi.org\/10.1590\/0074-02760230143 (2023).","journal-title":"Mem. Inst. Oswaldo Cruz"},{"key":"79136_CR31","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3389\/fimmu.2020.00036","volume":"11","author":"JD Moreira","year":"2020","unstructured":"Moreira, J. D. et al. Functional inhibition of host histone deacetylases (HDACs) enhances in vitro and in vivo anti-mycobacterial activity in human macrophages and in zebrafish. Front. Immunol. 11, 36. https:\/\/doi.org\/10.3389\/fimmu.2020.00036 (2020).","journal-title":"Front. Immunol."},{"key":"79136_CR32","doi-asserted-by":"publisher","first-page":"102062","DOI":"10.1016\/j.tube.2021.102062","volume":"127","author":"M Campo","year":"2021","unstructured":"Campo, M. et al. HDAC3 inhibitor RGFP966 controls bacterial growth and modulates macrophage signaling during Mycobacterium tuberculosis infection. Tuberculosis (Edinb). 127, 102062. https:\/\/doi.org\/10.1016\/j.tube.2021.102062 (2021).","journal-title":"Tuberculosis (Edinb)"},{"key":"79136_CR33","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ijid.2018.02.021","volume":"69","author":"M Rao","year":"2018","unstructured":"Rao, M., Valentini, D., Zumla, A. & Maeurer, M. Evaluation of the efficacy of valproic acid and suberoylanilide hydroxamic acid (vorinostat) in enhancing the effects of first-line tuberculosis drugs against intracellular Mycobacterium tuberculosis. Int. J. Infect. Dis. 69, 78\u201384. https:\/\/doi.org\/10.1016\/j.ijid.2018.02.021 (2018).","journal-title":"Int. J. Infect. Dis."},{"key":"79136_CR34","doi-asserted-by":"publisher","unstructured":"Wang, X., Tang, X., Zhou, Z. & Huang, Q. Histone deacetylase 6 inhibitor enhances resistance to Mycobacterium tuberculosis infection through innate and adaptive immunity in mice. Pathog Dis. 76 https:\/\/doi.org\/10.1093\/femspd\/fty064 (2018).","DOI":"10.1093\/femspd\/fty064"},{"key":"79136_CR35","doi-asserted-by":"publisher","first-page":"602","DOI":"10.3389\/fimmu.2017.00602","volume":"8","author":"RC Moores","year":"2017","unstructured":"Moores, R. C., Brilha, S., Schutgens, F., Elkington, P. T. & Friedland, J. S. Epigenetic regulation of Matrix Metalloproteinase-1 and \u2013\u20093 expression in Mycobacterium tuberculosis infection. Front. Immunol. 8, 602. https:\/\/doi.org\/10.3389\/fimmu.2017.00602 (2017).","journal-title":"Front. Immunol."},{"key":"79136_CR36","doi-asserted-by":"publisher","first-page":"1121495","DOI":"10.3389\/fimmu.2023.1121495","volume":"14","author":"K Zhang","year":"2023","unstructured":"Zhang, K. et al. Sirtuin-dependent metabolic and epigenetic regulation of macrophages during tuberculosis. Front. Immunol. 14, 1121495. https:\/\/doi.org\/10.3389\/fimmu.2023.1121495 (2023).","journal-title":"Front. Immunol."},{"key":"79136_CR37","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/s42003-022-03387-9","volume":"5","author":"A Khan","year":"2022","unstructured":"Khan, A. et al. Human M1 macrophages express unique innate immune response genes after mycobacterial infection to defend against tuberculosis. Commun. Biol. 5, 480. https:\/\/doi.org\/10.1038\/s42003-022-03387-9 (2022).","journal-title":"Commun. Biol."},{"key":"79136_CR38","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/s41564-023-01335-9","volume":"8","author":"B Aylan","year":"2023","unstructured":"Aylan, B. et al. ATG7 and ATG14 restrict cytosolic and phagosomal Mycobacterium tuberculosis replication in human macrophages. Nat. Microbiol. 8, 803\u2013818. https:\/\/doi.org\/10.1038\/s41564-023-01335-9 (2023).","journal-title":"Nat. Microbiol."},{"key":"79136_CR39","doi-asserted-by":"publisher","unstructured":"Bhaskar, A. et al. Host sirtuin 2 as an immunotherapeutic target against tuberculosis. Elife. 9 https:\/\/doi.org\/10.7554\/eLife.55415 (2020).","DOI":"10.7554\/eLife.55415"},{"key":"79136_CR40","doi-asserted-by":"publisher","unstructured":"Roychowdhury, S., Gandhirajan, A., Kibler, C., Wang, X. & Vachharajani, V. Sirtuin 2 Dysregulates Autophagy in High-Fat-exposed Immune-Tolerant macrophages. Cells. 10 https:\/\/doi.org\/10.3390\/cells10040731 (2021).","DOI":"10.3390\/cells10040731"},{"key":"79136_CR41","doi-asserted-by":"publisher","unstructured":"Talukdar, S. et al. Mycobacterium tuberculosis exploits SIRT2 for iron acquisition to facilitate its intracellular survival. bioRxiv 2024.01.05.574348; doi: https:\/\/doi.org\/10.1101\/2024.01.05.574348","DOI":"10.1101\/2024.01.05.574348"},{"key":"79136_CR42","doi-asserted-by":"publisher","unstructured":"Cheng, C. Y. et al. Host sirtuin 1 regulates mycobacterial immunopathogenesis and represents a therapeutic target against tuberculosis. Sci. Immunol. 2 https:\/\/doi.org\/10.1126\/sciimmunol.aaj1789 (2017).","DOI":"10.1126\/sciimmunol.aaj1789"},{"key":"79136_CR43","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.abb.2019.04.006","volume":"667","author":"H Yang","year":"2019","unstructured":"Yang, H., Hu, J., Chen, Y. J. & Ge, B. Role of Sirt1 in innate immune mechanisms against Mycobacterium tuberculosis via the inhibition of TAK1 activation. Arch. Biochem. Biophys. 667, 49\u201358. https:\/\/doi.org\/10.1016\/j.abb.2019.04.006 (2019).","journal-title":"Arch. Biochem. Biophys."},{"key":"79136_CR44","doi-asserted-by":"publisher","first-page":"4712","DOI":"10.1128\/MCB.00657-10","volume":"30","author":"TT Schug","year":"2010","unstructured":"Schug, T. T. et al. Myeloid deletion of SIRT1 induces inflammatory signaling in response to environmental stress. Mol. Cell. Biol. 30, 4712\u20134721. https:\/\/doi.org\/10.1128\/MCB.00657-10 (2010).","journal-title":"Mol. Cell. Biol."},{"key":"79136_CR45","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.4161\/auto.26336","volume":"9","author":"ML Chen","year":"2013","unstructured":"Chen, M. L. et al. Resveratrol attenuates vascular endothelial inflammation by inducing autophagy through the cAMP signaling pathway. Autophagy. 9, 2033\u20132045. https:\/\/doi.org\/10.4161\/auto.26336 (2013).","journal-title":"Autophagy"},{"key":"79136_CR46","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/sj.onc.1209049","volume":"25","author":"H Ota","year":"2006","unstructured":"Ota, H. et al. Sirt1 inhibitor, Sirtinol, induces senescence-like growth arrest with attenuated Ras-MAPK signaling in human cancer cells. Oncogene. 25, 176\u2013185. https:\/\/doi.org\/10.1038\/sj.onc.1209049 (2006).","journal-title":"Oncogene"},{"key":"79136_CR47","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1007\/s10495-019-01559-3","volume":"24","author":"N Mu","year":"2019","unstructured":"Mu, N. et al. Inhibition of SIRT1\/2 upregulates HSPA5 acetylation and induces pro-survival autophagy via ATF4-DDIT4-mTORC1 axis in human lung cancer cells. Apoptosis. 24, 798\u2013811. https:\/\/doi.org\/10.1007\/s10495-019-01559-3 (2019).","journal-title":"Apoptosis"},{"key":"79136_CR48","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.4110\/in.2022.22.e21","volume":"22","author":"Y Zhou","year":"2022","unstructured":"Zhou, Y., Zhang, F. & Ding, J. As a Modulator, Multitasking roles of SIRT1 in Respiratory diseases. Immune Netw. 22, e21. https:\/\/doi.org\/10.4110\/in.2022.22.e21 (2022).","journal-title":"Immune Netw."},{"key":"79136_CR49","doi-asserted-by":"publisher","first-page":"174264","DOI":"10.1016\/j.ejphar.2021.174264","volume":"907","author":"Y Wan","year":"2021","unstructured":"Wan, Y. et al. Tenovin-1 inhibited dengue virus replication through SIRT2. Eur. J. Pharmacol. 907, 174264. https:\/\/doi.org\/10.1016\/j.ejphar.2021.174264 (2021).","journal-title":"Eur. J. Pharmacol."},{"key":"79136_CR50","doi-asserted-by":"publisher","first-page":"283","DOI":"10.4062\/biomolther.2018.107","volume":"27","author":"M Bang","year":"2019","unstructured":"Bang, M. et al. Tenovin-1 induces senescence and decreases Wound-Healing activity in cultured rat primary astrocytes. Biomol. Ther. (Seoul). 27, 283\u2013289. https:\/\/doi.org\/10.4062\/biomolther.2018.107 (2019).","journal-title":"Biomol. Ther. (Seoul)"},{"key":"79136_CR51","doi-asserted-by":"publisher","first-page":"3334","DOI":"10.7150\/ijbs.97304","volume":"20","author":"S Sharma","year":"2024","unstructured":"Sharma, S. et al. Tenovin-1, a selective SIRT1\/2 inhibitor, attenuates high-fat Diet-induced hepatic fibrosis via inhibition of HSC activation in ZDF rats. Int. J. Biol. Sci. 20, 3334\u20133352. https:\/\/doi.org\/10.7150\/ijbs.97304 (2024).","journal-title":"Int. J. Biol. Sci."},{"key":"79136_CR52","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1159\/000484119","volume":"43","author":"L Tang","year":"2017","unstructured":"Tang, L. et al. Suppression of Sirtuin-1 increases IL-6 expression by activation of the akt pathway during allergic asthma. Cell. Physiol. Biochem. 43, 1950\u20131960. https:\/\/doi.org\/10.1159\/000484119 (2017).","journal-title":"Cell. Physiol. Biochem."},{"key":"79136_CR53","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1016\/j.bbamcr.2013.03.004","volume":"1833","author":"J Lugrin","year":"2013","unstructured":"Lugrin, J. et al. The sirtuin inhibitor cambinol impairs MAPK signaling, inhibits inflammatory and innate immune responses and protects from septic shock. Biochim. Biophys. Acta. 1833, 1498\u20131510. https:\/\/doi.org\/10.1016\/j.bbamcr.2013.03.004 (2013).","journal-title":"Biochim. Biophys. Acta"},{"key":"79136_CR54","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1093\/jac\/dku080","volume":"69","author":"A Nautiyal","year":"2014","unstructured":"Nautiyal, A., Patil, K. N. & Muniyappa, K. Suramin is a potent and selective inhibitor of Mycobacterium tuberculosis RecA protein and the SOS response: RecA as a potential target for antibacterial drug discovery. J. Antimicrob. Chemother. 69, 1834\u20131843. https:\/\/doi.org\/10.1093\/jac\/dku080 (2014).","journal-title":"J. Antimicrob. Chemother."},{"key":"79136_CR55","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1128\/iai.20.2.503-511.1978","volume":"20","author":"EL Pesanti","year":"1978","unstructured":"Pesanti, E. L. Suramin effects on macrophage phagolysosome formation and antimicrobial activity. Infect. Immun. 20, 503\u2013511. https:\/\/doi.org\/10.1128\/iai.20.2.503-511.1978 (1978).","journal-title":"Infect. Immun."},{"key":"79136_CR56","first-page":"118","volume":"63","author":"M Brandely","year":"1986","unstructured":"Brandely, M., Lagrange, P. H. & Hurtrel, B. Effects of suramin on the in vivo antimicrobial resistance against Listeria monocytogenes and Mycobacterium bovis (BCG) in mice. Clin. Exp. Immunol. 63, 118\u2013126 (1986).","journal-title":"Clin. Exp. Immunol."},{"key":"79136_CR57","doi-asserted-by":"publisher","first-page":"e1005007","DOI":"10.1371\/journal.ppat.1005007","volume":"11","author":"AK Coussens","year":"2015","unstructured":"Coussens, A. K., Wilkinson, R. J. & Martineau, A. R. Phenylbutyrate is bacteriostatic against Mycobacterium tuberculosis and regulates the macrophage response to infection, synergistically with 25-Hydroxy-vitamin D3. PLoS Pathog. 11, e1005007. https:\/\/doi.org\/10.1371\/journal.ppat.1005007 (2015).","journal-title":"PLoS Pathog"},{"key":"79136_CR58","doi-asserted-by":"publisher","first-page":"744416","DOI":"10.3389\/fmicb.2021.744416","volume":"12","author":"J Gallego-Jara","year":"2021","unstructured":"Gallego-Jara, J. et al. Bacterial sirtuins overview: an Open Niche to explore. Front. Microbiol. 12, 744416. https:\/\/doi.org\/10.3389\/fmicb.2021.744416 (2021).","journal-title":"Front. Microbiol."},{"key":"79136_CR59","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.1074\/mcp.M114.041962","volume":"13","author":"F Liu","year":"2014","unstructured":"Liu, F. et al. Acetylome analysis reveals diverse functions of lysine acetylation in Mycobacterium tuberculosis. Mol. Cell. Proteom. 13, 3352\u20133366. https:\/\/doi.org\/10.1074\/mcp.M114.041962 (2014).","journal-title":"Mol. Cell. Proteom."},{"key":"79136_CR60","doi-asserted-by":"publisher","first-page":"4441","DOI":"10.1021\/acs.jproteome.5b00359","volume":"14","author":"L Gu","year":"2015","unstructured":"Gu, L. et al. Functional characterization of Sirtuin-like protein in Mycobacterium smegmatis. J. Proteome Res. 14, 4441\u20134449. https:\/\/doi.org\/10.1021\/acs.jproteome.5b00359 (2015).","journal-title":"J. Proteome Res."},{"key":"79136_CR61","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3389\/fmicb.2011.00002","volume":"2","author":"SJ Sasindran","year":"2011","unstructured":"Sasindran, S. J. & Torrelles, J. B. Mycobacterium Tuberculosis infection and inflammation: what is Beneficial for the host and for the bacterium? Front. Microbiol. 2, 2. https:\/\/doi.org\/10.3389\/fmicb.2011.00002 (2011).","journal-title":"Front. Microbiol."},{"key":"79136_CR62","doi-asserted-by":"publisher","unstructured":"Domingo-Gonzalez, R., Prince, O., Cooper, A. & Khader, S. A. Cytokines and chemokines in Mycobacterium tuberculosis infection. Microbiol. Spectr. 4 https:\/\/doi.org\/10.1128\/microbiolspec.TBTB2-0018-2016 (2016).","DOI":"10.1128\/microbiolspec.TBTB2-0018-2016"},{"key":"79136_CR63","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.jinf.2008.08.010","volume":"57","author":"P Mendez-Samperio","year":"2008","unstructured":"Mendez-Samperio, P. Expression and regulation of chemokines in mycobacterial infection. J. Infect. 57, 374\u2013384. https:\/\/doi.org\/10.1016\/j.jinf.2008.08.010 (2008).","journal-title":"J. Infect."},{"key":"79136_CR64","doi-asserted-by":"publisher","unstructured":"Olsen, A. et al. Targeting Mycobacterium tuberculosis Tumor necrosis factor alpha-downregulating genes for the development of Antituberculous vaccines. mBio. 7 https:\/\/doi.org\/10.1128\/mBio.01023-15 (2016).","DOI":"10.1128\/mBio.01023-15"},{"key":"79136_CR65","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1007\/BF03401576","volume":"1","author":"JM Tramontana","year":"1995","unstructured":"Tramontana, J. M. et al. Thalidomide treatment reduces tumor necrosis factor alpha production and enhances weight gain in patients with pulmonary tuberculosis. Mol. Med. 1, 384\u2013397 (1995).","journal-title":"Mol. Med."},{"key":"79136_CR66","doi-asserted-by":"publisher","DOI":"10.1101\/2023.02.07.23285472","author":"F Hamilton","year":"2023","unstructured":"Hamilton, F. et al. Altered IL-6 signalling and risk of tuberculosis disease: a meta-analysis and mendelian randomisation study. medRxiv. https:\/\/doi.org\/10.1101\/2023.02.07.23285472 (2023).","journal-title":"medRxiv"},{"key":"79136_CR67","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/0092-8674(95)90418-2","volume":"80","author":"T Tanaka","year":"1995","unstructured":"Tanaka, T. et al. Targeted disruption of the NF-IL6 gene discloses its essential role in bacteria killing and tumor cytotoxicity by macrophages. Cell. 80, 353\u2013361. https:\/\/doi.org\/10.1016\/0092-8674(95)90418-2 (1995).","journal-title":"Cell"},{"key":"79136_CR68","doi-asserted-by":"publisher","first-page":"e94188","DOI":"10.1371\/journal.pone.0094188","volume":"9","author":"MR Fernando","year":"2014","unstructured":"Fernando, M. R., Reyes, J. L., Iannuzzi, J., Leung, G. & McKay, D. M. The pro-inflammatory cytokine, interleukin-6, enhances the polarization of alternatively activated macrophages. PLoS One. 9, e94188. https:\/\/doi.org\/10.1371\/journal.pone.0094188 (2014).","journal-title":"PLoS One"},{"key":"79136_CR69","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1093\/infdis\/jiad390","volume":"229","author":"KG Nore","year":"2024","unstructured":"Nore, K. G. et al. The cyclooxygenase 2 inhibitor etoricoxib as adjunctive therapy in Tuberculosis impairs Macrophage Control of Mycobacterial Growth. J. Infect. Dis. 229, 888\u2013897. https:\/\/doi.org\/10.1093\/infdis\/jiad390 (2024).","journal-title":"J. Infect. Dis."},{"key":"79136_CR70","doi-asserted-by":"publisher","first-page":"849583","DOI":"10.3389\/fimmu.2022.849583","volume":"13","author":"W Wang","year":"2022","unstructured":"Wang, W. et al. Mycobacterium tuberculosis-Induced Upregulation of the COX-2\/mPGES-1 pathway in human macrophages is abrogated by Sulfasalazine. Front. Immunol. 13, 849583. https:\/\/doi.org\/10.3389\/fimmu.2022.849583 (2022).","journal-title":"Front. Immunol."},{"key":"79136_CR71","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s12866-021-02212-3","volume":"21","author":"S Kalsum","year":"2021","unstructured":"Kalsum, S., Andersson, B., Das, J., Schon, T. & Lerm, M. A high-throughput screening assay based on automated microscopy for monitoring antibiotic susceptibility of Mycobacterium tuberculosis phenotypes. BMC Microbiol. 21, 167. https:\/\/doi.org\/10.1186\/s12866-021-02212-3 (2021).","journal-title":"BMC Microbiol."},{"key":"79136_CR72","doi-asserted-by":"publisher","first-page":"101977","DOI":"10.1016\/j.tube.2020.101977","volume":"124","author":"B Andersson","year":"2020","unstructured":"Andersson, B., Nordvall, M. J., Welin, A., Lerm, M. & Schon, T. A novel mycobacterial growth inhibition assay employing live-cell imaging of virulent M. Tuberculosis and monitoring of host cell viability. Tuberculosis (Edinb). 124, 101977. https:\/\/doi.org\/10.1016\/j.tube.2020.101977 (2020).","journal-title":"Tuberculosis (Edinb)"},{"key":"79136_CR73","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1080\/15592294.2019.1603963","volume":"14","author":"J Das","year":"2019","unstructured":"Das, J., Verma, D., Gustafsson, M. & Lerm, M. Identification of DNA methylation patterns predisposing for an efficient response to BCG vaccination in healthy BCG-naive subjects. Epigenetics. 14, 589\u2013601. https:\/\/doi.org\/10.1080\/15592294.2019.1603963 (2019).","journal-title":"Epigenetics"},{"key":"79136_CR74","doi-asserted-by":"publisher","first-page":"12305","DOI":"10.1038\/s41598-017-12110-2","volume":"7","author":"D Verma","year":"2017","unstructured":"Verma, D. et al. Anti-mycobacterial activity correlates with altered DNA methylation pattern in immune cells from BCG-vaccinated subjects. Sci. Rep. 7, 12305. https:\/\/doi.org\/10.1038\/s41598-017-12110-2 (2017).","journal-title":"Sci. Rep."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-79136-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-79136-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-79136-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T10:07:28Z","timestamp":1731665248000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-79136-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,15]]},"references-count":74,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["79136"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-79136-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,15]]},"assertion":[{"value":"31 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.This study was supported by the Swedish Heart and Lung Foundation (HLF) (2019\u2009\u2212\u20090302 and<sup>51<\/sup>2022\u2009\u2212\u20090484 to S.B.), the Swedish Research Council (VR) (2019\u2009\u2212\u200901744 and 2022\u2009\u2212\u200900970 to S.B.), Karolinska Institutet KID funding (2018\u2009\u2212\u200900830 to S.B.) and the Foundation to Prevent Antibiotic Resistance. The funders had no role in study design, experimental works, data analysis, decision to publish, or preparation of the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"28150"}}